Table 3.
Baseline information of ACPA-positive participants divided by CSQ data concerning joint complaints (N = 178)
| Baseline | Joint complaints (N = 83) | No joint complaints (N = 95) | P-value |
|---|---|---|---|
| Age, years, median (IQR) | 49 (43–56) | 44 (34–51) | 0.005 |
| Gender (female), n (%) | 60 (72.2) | 52 (54.7) | 0.01 |
| BMI, kg/m2, median (IQR) | 25.1 (23.2–27.70 | 24.5 (22.6–26.9) | 0.21 |
| Smoking | |||
| Never smoker, n (%) | 30 (36.1) | 46 (48.4) | 0.10 |
| Former smoker, n (%) | 37 (44.6) | 30 (31.6) | 0.08 |
| Current smoker, n (%) | 16 (19.3) | 19 (20) | 0.90 |
| Alcohol (g/day), median (IQR) | 3.57 (0–7.14) | 3.57 (0–8.57) | 0.89 |
| Periodontitis (self-reported), n (%) | 14 (16.8) | 13 (13.7) | 0.56 |
| Joint complaints: pain hands and/or feet, n (%) | 33 (39.8) | 6 (6.3) | <0.001 |
| Joint complaints: stiffness in hands and/or feet, n (%) | 29 (34.9) | 8 (8.4) | <0.001 |
| FDR with rheumatism, n (%) | 21 (25.3) | 13 (13.6) | 0.05 |
| ACPA IgG pos, n (%) | 83 (100) | 95 (100) | NA |
| ACPA IgG level, median (IQR) | 19 (9.0–64.0) | 17.0(8.0–61.0) | 0.39 |
| ACPA IgA pos n (%) | 47 (56.6) | 50 (52.6) | 0.61 |
| ACPA IgA level, median (IQR) | 1.1 (0.6–2.4) | 1.1 (0.6–1.9) | 0.61 |
| RF IgA pos, n (%) | 21 (25.3) | 19 (20.0) | 0.42 |
| RF IgA level, median (IQR) | 6.7 (2.0–25.5) | 3.0 (1.2–17.3) | 0.03 |
| RF IgM pos (>3.5), n (%) | 42 (50.6) | 28(29.5) | 0.005 |
| RF IgM pos (>10.0), n (%) | 28 (33.7) | 20 (21.1) | 0.06 |
| RF IgM level, median (IQR) | 4.0 (1.1–17.5) | 2.3 (0.6–8.5) | 0.03 |
| Anti-CarP pos, n (%) | 13 (15.6) | 12 (12.6) | 0.44 |
| Anti-CarP level, median (IQR) | 100 (46–237) | 89 (43–287) | 0.46 |
Significant P values are shown in bold. CSQ: CTD Screening Questionnaire; IQR: interquartile range; anti-CarP: anti-carbamylated protein antibody; FDR: first-degree relative; pos: positive; NA: not applicable.